Literature DB >> 18569082

Effect of naturally occurring triterpenoids ursolic acid and glycyrrhizic acid on the cell-mediated immune responses of metastatic tumor-bearing animals.

T J Raphael1, G Kuttan.   

Abstract

Effect of terpenoids, ursolic acid and glycyrrhizic acid on the cell-mediated immune response was studied in metastatic tumor-bearing C57BL/6 mice. Intraperitoneal administration of ursolic acid and glycyrrhizic acid (50 mumoles/Kg body wt for 5 consecutive days) was found to produce increased natural killer cell activity (NK-activity) in metastatic tumor-bearing animals. In the glycyrrhizic acid- and ursolic acid-treated groups the peak activity was observed on the 4(th) day (60.2% and 43% cell lysis respectively). Whereas in control animals the maximum cell lysis was obtained only on 16(th) day (25% cell lysis). Administration of terpenoids clearly enhanced the antibody dependent cell mediated cytotoxicity (ADCC). In tumor-bearing control animals maximum cell lysis was obtained only on the 16(th) day (20% cell lysis). But in the case of glycyrrhizic acid- and ursolic acid-treated groups, the maximum lysis was obtained on the 12(th) day. and it was 47% and 32.5% cell lysis, respectively. Intraperitoneal administration of these 2 terpenoids was also found to enhance antibody-dependent complement-mediated cytotoxicity (ACC) in metastatic tumor-bearing animals. The elevated level of GM-CSF in tumor-alone treated control animals (37.9 +/- 1.1 pg/ml) was reduced by the treatment with glycyrrhizic acid (20.3 pg/ml) and ursolic acid (22.5 pg/ml). The highly elevated level of IL-6 (370.1 pg/ml) in control animals was also reduced by the treatment of glycyrrhizic acid (313 pg/ml) and ursolic acid (299 pg/ml). The level of IL-2 was enhanced by the treatment with glycyrrhizic acid (37.9 pg/ml) and ursolic acid (35.9) compared to untreated tumor-bearing control animals (24.9 pg/ml).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18569082     DOI: 10.1080/08923970701675044

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  7 in total

1.  Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling.

Authors:  Si-Qi He; Meng Gao; Yun-Feng Fu; Ya-Nan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 2.  Cancer prevention with promising natural products: mechanisms of action and molecular targets.

Authors:  Poyil Pratheeshkumar; Chakkenchath Sreekala; Zhuo Zhang; Amit Budhraja; Songze Ding; Young-Ok Son; Xin Wang; Andrew Hitron; Kim Hyun-Jung; Lei Wang; Jeong-Chae Lee; Xianglin Shi
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

3.  Anti-allergic activity of glycyrrhizic acid on IgE-mediated allergic reaction by regulation of allergy-related immune cells.

Authors:  Shiwen Han; Lu Sun; Feng He; Huilian Che
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

4.  Autophagy inhibition enhances the inhibitory effects of ursolic acid on lung cancer cells.

Authors:  Min Wang; Hong Yu; Ran Wu; Zhen-Yin Chen; Qian Hu; Yan-Fei Zhang; San-Hui Gao; Guang-Biao Zhou
Journal:  Int J Mol Med       Date:  2020-08-28       Impact factor: 4.101

Review 5.  Immunomodulatory properties of triterpenes.

Authors:  Gülin Renda; İçim Gökkaya; Didem Şöhretoğlu
Journal:  Phytochem Rev       Date:  2021-11-18       Impact factor: 7.741

6.  The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma.

Authors:  Xuan Zhang; Hua Yang; Shuqiang Yue; Guangbin He; Shibin Qu; Zhuochao Zhang; Ben Ma; Rui Ding; Wei Peng; Hongtao Zhang; Zhaoxu Yang; Kefeng Dou; Kaishan Tao; Xiao Li
Journal:  Cancer Med       Date:  2017-07-03       Impact factor: 4.452

7.  Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune®) in TRAMP Mice.

Authors:  Peihe Liang; Jia Guo; Shadan Li; Qiunong Guan; Terry Vanderheyden; Alan So; Yuzhuo Wang; Tao Chen; Caigan Du
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-14       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.